We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aduro (ADRO) Q3 Loss In Line With Estimates, Revenues Miss
Read MoreHide Full Article
Aduro BioTech, Inc. reported third-quarter 2017 loss of 33 cents per share, in line with the Zacks Consensus Estimate but narrower than the year-ago loss of 54 cents per share.
Quarterly revenues fell 2.4% year over year to $3.7 million. The top line also missed the Zacks Consensus Estimate of $4.18 million. In July, the company recognized a milestone payment of $2 million from Merck & Co (MRK - Free Report) related to development of Aduro’s anti-CD27 antibody.
Aduro’s shares have underperformed the industry so far this year. The stock has declined 30.3% while the industry registered an increase of 3.3%.
Research and development expenses showed a substantial increase of 28.4% in the quarter to $24.5 million, mainly due to an increase in costs related to manufacturing of B-select antibodies and higher facility related costs.
General and administrative expenses were $8.5 million, down 1.1% year over year due to lower consulting and professional fees.
Pipeline Update
Aduro has a broad pipeline of novel immunotherapies under development for the treatment of a variety of cancers.
The company initiated a phase I study in September to evaluate personalized live, attenuated double-deleted Listeria monocytogenes (pLADD)-based immunotherapy. The immunotherapy, which uses patient-specific antigens, will be studied in patients with microsatellite stable metastatic colorectal cancer. Aduro’s most advanced LADD candidate, CRS-207, is being evaluated in combination with Bristol-Myers Squibb Company’s (BMY - Free Report) Opdivo in two separate phase II studies for gastric cancer and mesothelioma. Data from mesothelioma study is expected by the end of this year.
Meanwhile, the company initiated a phase Ib study to evaluate its STING pathway activator, ADU-S100, in combination with Novartis AG’s (NVS - Free Report) PD-1 checkpoint inhibitor, PDR001, for treating solid tumors and lymphomas.
During the quarter, Aduro announced that the FDA has cleared the investigational new drug application ("IND") for anti-APRIL antibody, BION-1301. The company expects to initiate a phase I study by 2017.
Aduro Biotech, Inc. Price, Consensus and EPS Surprise
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Aduro (ADRO) Q3 Loss In Line With Estimates, Revenues Miss
Aduro BioTech, Inc. reported third-quarter 2017 loss of 33 cents per share, in line with the Zacks Consensus Estimate but narrower than the year-ago loss of 54 cents per share.
Quarterly revenues fell 2.4% year over year to $3.7 million. The top line also missed the Zacks Consensus Estimate of $4.18 million. In July, the company recognized a milestone payment of $2 million from Merck & Co (MRK - Free Report) related to development of Aduro’s anti-CD27 antibody.
Aduro’s shares have underperformed the industry so far this year. The stock has declined 30.3% while the industry registered an increase of 3.3%.
Research and development expenses showed a substantial increase of 28.4% in the quarter to $24.5 million, mainly due to an increase in costs related to manufacturing of B-select antibodies and higher facility related costs.
General and administrative expenses were $8.5 million, down 1.1% year over year due to lower consulting and professional fees.
Pipeline Update
Aduro has a broad pipeline of novel immunotherapies under development for the treatment of a variety of cancers.
The company initiated a phase I study in September to evaluate personalized live, attenuated double-deleted Listeria monocytogenes (pLADD)-based immunotherapy. The immunotherapy, which uses patient-specific antigens, will be studied in patients with microsatellite stable metastatic colorectal cancer. Aduro’s most advanced LADD candidate, CRS-207, is being evaluated in combination with Bristol-Myers Squibb Company’s (BMY - Free Report) Opdivo in two separate phase II studies for gastric cancer and mesothelioma. Data from mesothelioma study is expected by the end of this year.
Meanwhile, the company initiated a phase Ib study to evaluate its STING pathway activator, ADU-S100, in combination with Novartis AG’s (NVS - Free Report) PD-1 checkpoint inhibitor, PDR001, for treating solid tumors and lymphomas.
During the quarter, Aduro announced that the FDA has cleared the investigational new drug application ("IND") for anti-APRIL antibody, BION-1301. The company expects to initiate a phase I study by 2017.
Aduro Biotech, Inc. Price, Consensus and EPS Surprise
Aduro Biotech, Inc. Price, Consensus and EPS Surprise | Aduro Biotech, Inc. Quote
Zacks Rank
Aduro currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>